Drug
DS 1103a
DS 1103a: highest development phase Phase 1/2, developed by Daiichi Sankyo. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Daiichi Sankyo
Trials
| Drug | Phase | Indication |
|---|---|---|
| DS-1103a NCT07739966 | Phase 1/2 | Solid Tumor |
Latest
No recent events.
Follow DS 1103a on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.